No Data
BEIGENE (06160) JPM 2025 releases Bullish news, multiple international investment banks remain Bullish on the company's prospects.
At the JPM Conference in 2025, BEIGENE management clearly provided guidance on the timeline for profitability, expecting to achieve GAAP operating profit break-even in 2025, one year earlier than market expectations.
BeiGene, Ltd.'s (NASDAQ:ONC) Profit Outlook
BeiGene Enters Sublease Agreement With ChemoCentryx for Expansion
BEIGENE (06160.HK) subsidiary signs a sublease agreement with Chemo Centryx.
On January 20, Gelonghui announced that BEIGENE (06160.HK) signed a sublease agreement on January 17, 2025 (USA time) between a wholly-owned subsidiary BEIGENE US (as lessee) and Chemo Centryx (as sublessor), whereby Chemo Centryx agreed to sublease the property to BEIGENE US. The lease term shall commence from the effective date of the sublease until the expiration date of the sublease. Subleased property: Approximately 96,372 square feet of rentable space, including about 49,820 square feet on the fifth floor and the sixth floor.
BeiGene Announces Board Composition and Committee Roles
BEIGENE (06160.HK): Anthony C. Hooper has been appointed as the chairman of the Nomination and Corporate Governance Committee.
On January 20, Gelonghui reported that BEIGENE (06160.HK) announced that its independent non-executive director, Ms. Shalini Sharp, has been appointed as a member of the Nomination and Corporate Governance Committee, and its independent non-executive director, Mr. Anthony C. Hooper, has been appointed as the chairman of the Nomination and Corporate Governance Committee, effective from January 16, 2025 (USA time).
